11 citations,
May 2021 in “Journal of The American Academy of Dermatology” COVID-19 doesn't make alopecia areata worse.
11 citations,
February 2021 in “Journal of Cosmetic Dermatology” Oral tofacitinib helped regrow hair in over half of the patients with severe alopecia, but relapses and side effects were common.
11 citations,
November 2019 in “Journal of the American Academy of Dermatology” Oral tofacitinib is a promising treatment for beard hair loss in alopecia areata.
11 citations,
December 2018 in “Journal of the European Academy of Dermatology and Venereology” Stopping JAK inhibitor treatment for hair loss can lead to worse hair loss than before the treatment.
11 citations,
January 2018 in “Acta dermato-venereologica” Tofacitinib works better and is more tolerable for severe alopecia than conventional treatments and DPCP immunotherapy.
10 citations,
September 2014 in “European Journal of Dermatology” A woman's hair loss worsened after starting hepatitis C treatment due to immune changes in her hair follicles.
10 citations,
January 2023 in “Acta dermato-venereologica” Baricitinib and deuruxolitinib are effective for treating alopecia areata, but their efficacy depends on the dose.
9 citations,
October 2021 in “International Journal of Dermatology” Tofacitinib is effective and safe for treating severe hair loss in a Saudi population.
9 citations,
May 2021 in “International Journal of Dermatology” The trial showed that a new under-the-tongue treatment for severe hair loss was somewhat effective in a small group of people.
9 citations,
June 2019 in “Archives of Dermatological Research” Both topical calcipotriol and narrowband UVB improved alopecia, but combining them didn't enhance the effect on hair loss severity, despite higher vitamin D3 levels.
9 citations,
January 2019 in “International Journal of Trichology” Combining calcipotriol with mometasone is more effective for treating alopecia areata than using mometasone alone.
6 citations,
May 2023 in “Drugs” Baricitinib helps regrow hair in adults with severe alopecia better than a placebo and is approved for treatment, but long-term effects are still unknown.
6 citations,
February 2021 in “Advances in Clinical and Experimental Medicine” Wharton's jelly-derived stem cells were safely used to treat four alopecia patients, resulting in hair regrowth in all of them.
5 citations,
October 2021 in “Clinical, cosmetic and investigational dermatology” Japanese patients with alopecia areata often have a higher BMI and consume more vitamin C, fruit, and retinol, which may affect their condition's development or severity.
5 citations,
April 2019 in “Journal of Nepal Health Research Council” People with Alopecia areata often have lower vitamin D levels, which may be linked to the severity of their condition.
5 citations,
August 2018 in “PubMed” An 8-year-old with severe hair loss regrew all hair after six months of tofacitinib treatment.
4 citations,
January 2024 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” Baricitinib and ritlecitinib are recommended for severe alopecia areata, with other treatments available off-label.
4 citations,
September 2022 in “Journal of The American Academy of Dermatology” Baricitinib was effective in regrowing hair in patients with different levels of alopecia areata severity.
4 citations,
June 2023 in “Frontiers in immunology” JAK inhibitors help hair regrowth in alopecia areata but have a high risk of side effects.
3 citations,
June 2023 in “Journal of dermatological treatment” Regrowing scalp hair improves quality of life and reduces anxiety and depression in severe alopecia areata patients.
3 citations,
April 2023 in “Dermatologica Sinica” PRP treatment may help with alopecia areata, especially in newer cases.
3 citations,
September 2022 in “Archives of dermatological research” The fractional carbon dioxide laser is a safe and effective treatment for alopecia areata and works better than betamethasone valerate cream alone.
3 citations,
September 2022 in “Journal of the American Academy of Dermatology” Baricitinib is effective and safe for severe alopecia areata, working similarly with or without an atopic background.
3 citations,
September 2021 in “Journal of Investigative Dermatology” Baricitinib was more effective than a placebo in regrowing hair in adults with alopecia areata after 36 weeks.
3 citations,
October 2020 in “The journal of investigative dermatology. Symposium proceedings/The Journal of investigative dermatology symposium proceedings” Alopecia areata is a hair loss disease caused by complex immune reactions, and new targeted treatments show promise.
2 citations,
August 2020 in “Journal of Cosmetic Dermatology” Higher granulysin levels in the blood are linked to more severe hair loss in alopecia areata patients, and these levels decrease after effective treatment.
2 citations,
July 2023 in “Journal of cosmetic dermatology” JAK inhibitors are more effective and safer for treating alopecia areata than dupilumab and apremilast.
2 citations,
January 2023 in “Dermatology Practical & Conceptual” AB+ blood group is more common in alopecia areata patients.
2 citations,
September 2022 in “Dermatologic Therapy” Tofacitinib is a promising treatment for severe alopecia areata, with many patients experiencing complete or partial hair regrowth.
2 citations,
August 2022 in “JAAD case reports” COVID-19 vaccines may rarely worsen hair loss in people with severe alopecia, but the benefits of vaccination still outweigh this risk.